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Abstract
Background: Angiostatic/antiinflammatory therapy with COX-II inhibitors and pioglitazone seems to be a well
tolerated and promising regimen in patients with metastatic cancer. COX-II inhibitors may have less gastrointestinal
side effects than conventional non-steroidal antiinflammatory drugs, but their impact on renal function seems to
be similar.
Methods: 87 patients with metastatic/advanced cancer were treated up to 12 months (mean 19.5 weeks) with
rofecoxib, pioglitazone and either capecitabine (group A with gastrointestinal and urological cancer, n = 50) or
trofosfamide (group B with non-gastrointestinal/non-urological cancer, n = 37) and followed for further 6 months.
Results: Baseline serum creatinine concentration was 0.81 ± 0.28 mg/dl, and increased by about 0.15 mg/dl during
months 1-3. Accordingly estimated glomerular filtration rate (eGFR) decreased from 90.3 ml/min ± 3.6 ml/min at
baseline by about 10 ml/min during months 1-3. Renal function decreased in 75 patients (86%) in the first month
(p < 0.0001). This decrease went along with clinical signs of volume expansion. Renal function tended to recover
after discontinuation of the study medication.
Conclusions: Therapy with rofecoxib in an antiangiogenic/antiinflammatory setting results in a decrease of renal
function in nearly every patient.
Trial registration number: German Clinical Trials Register DRKS: DRKS00000119
Background
Cyclooxygenases (both isoforms, COX-I and COX-II) oxi-
dize arachidonic acid to prostaglandin H2, which is con-
verted by different synthases to prostaglandin-E2, -D2, -I2,
-F2a, and thromboxane A2. These prostaglandins inhibit
apoptosis and promote cell division, metastasis and angio-
genesis leading to increased tumor growth [1]. An antian-
giogenic/antiinflammatory therapy with COX-II inhibitors
and pioglitazone combined with metronomic low-dose
chemotherapy with either capecitabine or trofosfamide
seems to be well tolerated and promising in patients with
advanced carcinomas [2,3]. However, in one study in
patients with colorectal cancer increased gastrointestinal
toxicity was reported [4]. Since COX-II inhibitors are
known to elicit renal side effects to a similar extent than
conventional non-steroidal antiinflammatory drugs [5], the
detailed analysis of any change in serum creatinine con-
centrations and glomerular filtration rate in a prospective
trial of antiangiogenic/antiinflammatory therapy in
advanced cancer was our primary objective.
Methods
Patient Characteristics
The study was approved by the local ethics committee,
and all patients gave their written informed consent for
study participation. Patients with either gastrointestinal/
urological cancer (group A, see Table 1) or with non-gas-
trointestinal/non-urological cancer (group B, see Table 1)
were included in the study and treated with rofecoxib,
pioglitazone and either capecitabine in a dose of 1.0 g bid
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(group A) or trofosfamide 50 mg tid (group B). Addi-
tional eligibility criteria have already been published [3].
Patients were recruited between 2000 and 2004. Treat-
ment was administered up to 12 months and patients
were followed up for further 6 months. 25 mg rofe-
coxib/day was administered to 75 patients, and a
reduced dose (12.5 mg/day) was administered to 12
patients with pre-existing renal impairment. Renal
impairment, that triggered a dose reduction of rofecoxib
in the prospective phase II trial, had been defined as any
serum creatinine concentration that exceeded the nor-
mal range. Serum creatinine concentrations were mea-
sured before inclusion of a patient and every month
thereafter. The normal range of serum creatinine
concentration in our institution is 05.-0.8 mg/dl for
women and 0.8-1.1 mg/dl for men.
Glomerular filtration rate was estimated using the
method of Cockcroft and Gault [6].
Provisions were made to reduce rofecoxib dose in case
of a rise in serum creatinine concentration above 1.3
mg/dl or WHO grade >1 edema.
The study was stopped because of withdrawal of rofe-
coxib from the market.
Statistics
We used the Wilcoxon signed rank test for the retro-
spective data analysis. Data are given as mean ± stan-
dard error of the mean.
Table 1 Baseline patient characteristics and underlying malignancy
Age in years (range) 60.5 (30 - 81)
Gender
Male 56 (64%)
Female 31 (36%)
Baseline serum creatinine concentration in
mg/dl (± SEM)
0.81 (± 0.28)
Arterial hypertension 21 (24%)
Concomitant nephrotoxic/volume depleting or blood pressure lowering medication
- NSAIDs 18 (21%)
- Loop diuretics 14 (16%)
- Thiazides 8 (9%)
- ACE inhibitor 6 (7%)
- AT2 blocker 4 (5%)
- Aldosterone antagonists 2 (2%)
Preceding chemotherapy 45 (52%)
Liver metastasis 45 (52%)
Group A (treated with capezitabine, rofecoxib
and pioglitazone)
Group B (treated with trofosfamid, rofecoxib
and pioglitazone)
Melanoma 16
Gastric carcinoma 13
Colorectal carcinoma 12
Renal cell carcinoma 9
Hepatic carcinoma/Klatskin 7
Sarcoma 5
Pulmonary adenocarcinoma/SCLC 3
Pancreatic cancer 3
Urothelium carcinoma 3
Gall bladder carcinoma 3
Breast cancer 2
Histiozytosis X 2
Hodgkin/Non-Hodgkin-Lymphoma 2
Ovarial carcinoma 2
TNE 2
Chronic lymphatic leukemia 1
Cervix carcinoma 1
SCLC = small cell lung cancer; TNE = throat nose ear.
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Results
Serum creatinine concentration and glomerular
filtration rate
Serum creatinine concentration increased in 75 patients
(86%) during the first month of the treatment phase
(p < 0.0001). This significant increase was sustained dur-
ing the first six months (Figure 1). After the end of
treatment, creatinine concentration significantly
decreased during months 1-3, but did not reach baseline
concentrations again (Figure 2).
Mean baseline eGFR decreased accordingly from
90.3 ml/min ± 3.6 ml/min at baseline to a minimum of
76 ml/min ± 5.4 ml/min in the fifth month (p = 0.0195)
(Figure 3). Two months after end of treatment with
rofecoxib, mean eGFR reached baseline values again
(96.6 ml/min ± 7.6 ml/min) (Figure 4).
In patients with pre-existing renal impairment, treated
with a reduced dose of rofecoxib the average serum
creatinine concentration rose from 1.01 mg/dl ± 0.1
mg/dl to a maximum of 1.25 mg/dl ± 0.27 mg/dl in the
fifth month (p = 0.0058).
Serum sodium concentrations
Serum sodium concentrations during rofecoxib therapy
remained unchanged. A decrease from 139.8 mmol/l ±
0.39 mmol/l to 137.0 mmol/l ± 1.28 mmol/l in month nine
(p = 0.006) appears to be a chance finding due to low num-
bers of patients remaining in the study. Serum sodium
concentration remained stable after treatment stop.
Body weight and edema formation
Mean body weight before treatment was 73.7 kg ± 1.7 kg,
fluctuated from month to month with a lower mean body
weight on month 2, 5 and 7, but increased significantly
during therapy with rofecoxib up to the eighth month with
10 patients remaining at risk. The highest increase in mean
body weight of 4.1 kg was noted in the eleventh month
after start of rofecoxib treatment with only 8 patients
remaining in the study. The increase in body weight went
along with edema formation in 30 patients (34%).
Immediately after discontinuation of treatment mean
body weight fell significantly from 74.2 kg ± 1.7 kg to
72.1 kg ± 2.5 kg.
Blood pressure
Mean systolic blood pressure rose during therapy from
130.1 mmHg ± 2.1 mmHg to 137.8 mmHg ± 6.2 mmHg
after twelve months except in months 2, 6, 7 and 10,
where the mean systolic blood pressure was at or lower
than baseline. In the first, second and fourth month
after cessation of rofecoxib therapy, mean systolic blood
pressure was significantly lower than during therapy.
Figure 1 Change of serum creatinine concentrations during
therapy. Increase of serum creatinine concentrations ± SEM
compared to baseline (0.81, ± 0.28 mg/dl) during therapy with
rofecoxib. *: p < 0.05.
Figure 2 Change of serum creatinine concentrations after end
of therapy. Decrease of mean serum creatinine concentrations ±
SEM after end of therapy with rofecoxib compared to the last day
of treatment. *: p < 0.05.
Figure 3 Change of glomerular filtration rate during therapy.
Decrease of estimated glomerular filtration rate ± SEM compared to
baseline (90.3 ml/min) during therapy with rofecoxib. *: p < 0.05.
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Mean diastolic blood pressure remained unchanged
throughout the trial.
Discussion
We found a significant increase in mean serum creati-
nine concentration (p < 0.0001) already in the first
month after initiation of treatment with rofecoxib. This
increase was sustained during treatment and ranged
around 0.15 mg/dl, corresponding to a decrease of
eGFR of around 10 ml/min, reaching up to 14 ml/min
in month 4. However, mean serum creatinine concen-
tration remained within the normal range during and
after end of the trial and no dialysis treatment was
needed. Rofecoxib is known to cause acute renal failure
at a rate of 1.2 to 1.5% in trials studying several thou-
sands of patients [7,8], but even a single dose of rofe-
coxib can cause severe acute renal failure [9].
Furthermore, the half life of COX-II inhibitors rofecoxib
and celecoxib is prolonged in liver failure [10]. Though
patients with severe hepatic failure were excluded from
the present study, 52% of the patients presented with
liver metastasis and thus might have been subjected to a
higher exposure of rofecoxib due to prolonged half life.
Progressive underlying malignant disease may as well
have contributed to functional prerenal failure i.e. due
to decreased fluid intake. The decreased renal function
however tended to normalize within 2 months after ces-
sation of rofecoxib therapy (Figure 2 and 4), suggesting
rofecoxib as the more likely cause of decreased renal
function, especially as we observed no severe nausea,
vomiting or diarrhea during the treatment phase.
We observed edema formation in 30 patients (34%),
which is above the rate observed in large studies ranging
between 7.7 and 23.3% [8,11,12] and which is possibly
due to the persistent decrease in renal function, the
well-known sodium- and/or fluid retaining properties of
COX-2 inhibitors and thiazolidindiones, and the under-
lying malignant disease with hypoproteinemia.
The rise in mean systolic blood pressure during therapy
corresponds to published data [13,14] and went along
with increasing body weight, probably both reflecting
renal impairment and subsequent fluid retention. Weight
gain is often seen in patients with diabetes treated with
pioglitazone [15] and pioglitazone may have contributed
to edema formation and the observed increase in body
weight in our study, but weight gain in our study popula-
tion is even more astonishing in regard of the underlying
malignancy which usually leads to progressive weight loss
as demonstrated after end of treatment.
Limitations
The antiinflammatory antiangiogenic therapy with a
COX-II inhibitor in combination with pioglitazone and
either trofosfamide or capecitabine seems to be both
well tolerated and promising with primary disease
response rates reaching up to 19% [3].
This study was stopped because of withdrawal of rofe-
coxib from the market, but the concept of an antiinflam-
matory antiangiogenic therapy with COX-II inhibitors
proves to be true also for other COX-II inhibitors like
celecoxib, still available on the market [16-18]. There are
also clearly class effects like prolonged half life in liver
failure [10] or decreasing renal function, which have been
shown for rofecoxib as well as for celecoxib [19].
The decrease in renal function in our study has to be
seen in the clinical context. A rise in mean serum crea-
tinine concentration of 0.15 mg/dl is of limited impor-
tance to young patients with normal body weight and
normal renal function. However, a mean fall in eGFR of
up to 14 ml/min nevertheless may urge the physician to
adapt the dose of concomitant medications or even stop
the treatment with a COX-II inhibitor especially in the
elderly patient with reduced body weight and pre-exist-
ing renal failure, suggesting the report of our results to
be of persistent importance even in the light of withdra-
wal of rofecoxib from the market.
Conclusion
We recommend close monitoring of renal function and
blood pressure of patients with cancer treated with
COX-II inhibitors, especially in a setting with pre-exist-
ing renal and hepatic failure.
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